Pegylated interferon-α2a treatment of chronic SIV-infected macaques

Journal of Medical Primatology

Volumn 37, Issue 1, 2008, Pages 26-30

  Asmuth, David M ^a   Abel, K ^a,b,c   George, M D ^d   Dandekar, S ^a,d   Pollard, R B ^a,d   Miller, C J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Innate immune responses; Interferon inducible molecules; Macaque; Pegylated interferon 2a; Simian immunodeficiency virus (SIV); TypeI interferons

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; MESSENGER RNA; PEGINTERFERON ALPHA2A; SODIUM CHLORIDE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; INTERFERON ALFA-2A; MACACA; MONKEY DISEASES; POLYETHYLENE GLYCOLS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIREMIA; VIRUS REPLICATION;

MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 38149027730     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2007.00221.x     Document Type: Article

References (22)

1. Abel K, Alegria-Hartman MJ, Rothaeusler K, Marthas M, Miller CJ: The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/ beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J Virol 2002; 76: 8433-45.
2. Abel K, Alegria-Hartman MJ, Zanotto K, McChesney MB, Marthas ML, Miller CJ: Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques. Cytokine 2001; 16: 191-204.
3. Akbar AN, Lord JM,ASalmon M: IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. Immunol Today 2000; 21: 337-42.
4. Biron CA: Role of early cytokines, including alpha and beta interferons (IFN- alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998; 10: 383-90.
5. Biron CA: Interferons alpha and beta as immune regulators - a new look. Immunity 2001; 14: 661-4.
6. Dailey PJ, Zamroud M, Kelso R, Kolberg J, Urdea M: Quantitation of simian immunodeficiency virus (SIV) RNA in plasma of acute and chronically infected rhesus macaques using a branched DNA (bDNA) signal amplification assay. Abstracts of the 13th Annual Symposium on Nonhuman Primate Models of AIDS, Monterey, CA, September, 1995; 180.
7. Dalod M, Hamilton T, Salomon R, Salazar-Mather TP, Henry SC, Hamilton JD, Biron CA: Dendritic cell responses to early murine cytomegalovirus infection: Subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 2003; 197: 885-98.
8. Dianzani F, Castilletti C, Gentile M, Gelderblom HR, Frezza F, Capobianchi MR: Effects of IFN α on late stages of HIV-1 replication cycle. Biochemie 1998; 80: 745-54.
9. EmiliéD, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, Rudent A, Molina JM, Livrozet JM, Souala F, Chene G, Grangeot-Keros L, Galanaud P, Sereni D, Rouzioux C and the Primoferon A Study Group. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNα: Results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15: 1345-7.
10. Frissen PH, de Wolf F, Reiss P, Bakker PJ, Veenhof CH, Danner SA, Goudsmit J, Lange JM: High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. J Infect Dis 1997; 176: 811-4.
11. Haas DW, LaVelle J, Nadler JP, Greenberg SB, Frame P, Mustafa N, St Clair M, McKinnis R, Dix L, Elkins M, Rooney J: A randomized trial of interferon α therapy for HIV type 1 infection. AIDS Res Hum Retroviruses 2000; 16: 183-90.
12. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT, Hirsch MS: Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1985; 1: 602-4.
13. Le Bon A., Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF: Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-15.
14. Le Bon A, Tough DF: Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002; 14: 432-6.
15. Nokta MA, Reichman RC, Pollard RB. Pathogenesis of viral infections. In: Antiviral Agents and Viral Diseases of Man, 3rd edn. Galasso, Whitley & Merigan (eds). New York: Raven Press, 1990; 49-85.
16. O'Shea JJ, Visconti R: Type I IFNs and regulation of TH1 responses: enigmas both resolved and emerge. Nat Immunol 2000; 1: 17-9.
17. Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 1987; 56: 727-77.
18. Schellekens H, Niphuis H, Buijs L, Douw vdK, Hochkeppel HK, Heeney JL: The effect of recombinant human interferon alpha B/D compared to interferon alpha 2b on SIV infection in rhesus macaques. Antiviral Res 1996; 32: 1-8.
19. Schellekens H, Weimar W, Cantell K, Stitz L: Antiviral effect of interferon in vivo may be mediated by the host. Nature 1979; 278: 742.
20. Schugt I, Dreuter A, SchAottmann R: Pegylated interferon alfa-2b: a new therapeutic option in the treatment of early-stage HIV infection [Abstract 59]. 10th Conference of Retroviruses & Opportunistic Infections, Boston, MA, 10-14 February, 2003; 78.
21. Wingfield C, Booth J, Sheridan P, Detmer J, Turczyn J: SIV 4.0, performance characteristics of an exceptionally sensitive, quantitative assay for SIV RNA using branched DNA technology. Abstracts of the 20th Annual Symposium on Nonhuman Primate Models of AIDS, Monterey, CA, September, 2002; 200.
22. Wright SE, Hutcheson DP, Cummins JM: Low dose oral interferon alpha 2a in HIV-1 seropositive patients: A double-blind, placebo-controlled trial. Biotherapy 1998; 11: 229-34.